Platyphylline hydrotartrate 0.2% 1ml. vials №10

Description

Platyphylline hydrotartrate Composition
Main active ingredients: Platyphylline hydrotartrate.
The auxiliary component is water for injection.

Release form
It is produced in the form of an injection solution in syringe tubes, with a volume of 1 ml and in a dosage of 2 mg of platyphylline hydrotartrate.

Pharmacological properties
This drug Platyphylline hydrotartrate belongs to a group of drugs that are used in the treatment of functional disorders of the gastrointestinal tract.
The main active component of the drug – platyphyllin – is an anticholinergic.
It has the property of blocking m-cholinergic receptors, turning them into insensitive to acetylcholines. Platyphylline hydrotartrate also has a direct myotropic spasmolytic papaverin-like effect on organs that have smooth muscles, including the intestines, bile ducts, bronchi, and eyes.
At the same time, there is a very weakly expressed activity in relation to smooth muscles in the blood vessels. Also, the drug produces a sedative effect due to its effects on the central nervous system, especially the vasomotor center. As a result, blood vessels dilate and blood pressure decreases.

Indications
It is used as an anticholinergic and antispasmodic drug, mainly for:

• spasms of smooth muscles of the abdominal organs – stomach, intestines, bile ducts and gallbladder, ureters);
• with stomach ulcers and 12 duodenal ulcers;
• bronchial asthma;
• increased tone and spasms of blood vessels (hypertension, angina pectoris, cerebrovascular accident, angiotrophoneurosis);
• with colic (renal, hepatic, intestinal);
• to dilate the pupil.

Contraindications
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or one of the auxiliary components.
It is contraindicated to use at:

• glaucoma;
• insufficiency of liver and kidney function;
• paralytic obstruction, intestinal atony;
• ulcerative colitis, myasthenia gravis;
• hypertrophy of the prostate gland.

Able to prolong the action of phenobarbital, magnesium sulfate, sodium etaminal.
Compatible with caffeine, cordiamine. Relieves side effects of morphine and verapamil.

Application during pregnancy and lactation
This drug is contraindicated for pregnant women, as well as when planning pregnancy.
If it is necessary to take the drug during breastfeeding, lactation is suspended.

Method of administration and dosage
Platyphylline hydrotartrate is administered subcutaneously.
It is used in case of attacks of a spastic nature in the stomach, gastrointestinal tract organs.
For the relief of acute ulcerative pain, intestinal, renal and hepatic colic, a prolonged attack of bronchial asthma, cerebral and peripheral angiospasms, platyphylline hydrotartrate is administered 1-2 ml of a 0.2% solution 1-2 times a day.
As an antispasmodic agent, this drug is prescribed 1 ml of a 0.2% solution daily for 1 month.
Maximum dosages:

• one-time – 10 mg;
• daily – 30 mg.

Overdose
In case of an overdose, you may experience:

• dry mouth, tachycardia, dilated pupils with no reaction to light;
• lowering blood pressure;
• difficulty urinating;
• intestinal atony, shortness of breath;
• convulsions, hyperthermia, redness of the skin;
• excitement of the central nervous system, followed by depression.

Overdose is treated with forced diuresis, administration of cholinesterase inhibitors.
In case of moderate overdose – use magnesium sulfate, in severe cases – sodium oxybutyrate, oxygen therapy, artificial ventilation.

Side effects
The use of the drug in high doses can cause side effects such as:

• tachycardia;
• dry mouth;
• intestinal atony;
• excitement of the central nervous system, dizziness, dilated pupils, violation of accommodation;
• difficulty urinating.

Storage conditions and periods
The shelf life is up to 2 years.
The storage temperature of Platyphylline hydrotartrate should not exceed 25 ° C.